The effect of Mongolian Medicine Chagan Gaoyou-4 Powder on bone mineral density induced by retinoic acid in rats
Abstract
Objective: To investigate the effects of Chagan-Gaoyou-4 powder on spine bone mineral density and serum estrogen and estrogen receptor alpha (ERa) and estrogen receptor beta (ERβ) protein expression in bone tissue induced by retinoic acid in rats. Methods: Sixty 3-month-old SPF female SD rats were randomly divided into model group (retinoin group), normal group (SHAM group), Mongolian medicine group (Chagan-Gaoyou 4 group), and control group (Gushukang granule group). After 14 days of administration, spinal Bone Mineral Density (BMD) was measured, and external manifestations were observed. Results: Compared with the SHAM group, the BMD values of all medication groups decreased (P < 0.05, P < 0.001). Compared with the model group, the spinal BMD value of the Chagan Gaoyou-4 group was increased after 21 days of treatment, and the difference was statistically significant (P < 0.01, P < 0.05). After 21 days, the spinal BMD value of all treatment groups was increased (P < 0.05), the spinal BMD value was also increased, especially Chagan Gaoyou-4 group was more obviously increased (P < 0.05). Compared with the normal group, ERa and ERβ levels in the model group were significantly decreased (P < 0.001), and ERa and ERβ levels in all drug groups were significantly increased (P < 0.001) compared with the model group. After 21 days of treatment, there was no significant difference among the three treatment groups (P > 0.05). ERa and ERβ levels in the Chagan Gaoyou-4 group were higher than those in the model group (P < 0.05), but there was no significant difference between the group and the Gushukang granule group (P > 0.05). The E2 content of the Chagan Gaoyou-4 group was higher than that of the model group (P < 0.05). The mRNA expression of estrogen receptor ERa and ERβ in bone tissue of the left proximal femur was detected by RT-PCR. Compared with the model group, the expression of ERa and ERβ mRNA in the Chagan Gaoyou-4 group and Gushukang granule group was increased. Compared with the model group, ERp mRNA expression was increased in the Chagan Gaoyou-4 powder medium-dose group. Compared with the Gushukang granule group, there was no significant difference in ERm RNA expression in the Chagan Gaoyou-4 dose groups. Chagan Gaoyou-4 can up-regulate the expression of ERa and ERβ induced by retinoic acid in rats, indicating that the Chagan Gaoyou-4 powder group may promote bone formation, regulate bone resorption, improve bone mineral density, and achieve the purpose of preventing and treating OP by increasing estrogen level, stimulating estrogen receptor, and increasing the expression of ERa and ERβ in bone tissue. Conclusion: Chagan-Gaoyu-4 powder may have estrogen-like effects on the bone tissue of rats induced by retinoic acid and may increase the level of serum estrogen, ERa, and ERβ protein expression, thereby improving the spinal BMD of experimental rats. The Chagan-Gaoyou-4 powder group could improve the general condition of osteoporosis induced by retinoic acid in rats.
References
1. Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association. Epidemiological Survey of Osteoporosis in China and Results of the “Healthy Skeletons” Special Action. Chinese Journal of Osteoporosis and Bone Mineral Disease. 2019; (4). doi: 10.3969/j.issn.1674-2591.2019.04.001
2. Editorial Committee of Mongolian Medicine Chinese Medical Encyclopedia. Mongolian Medicine. Shanghai: Shanghai Science and Technology Publishing House; 1992.12:244
3. Bao Shan. Study on the inheritance of Baoshan Bao Jingrong's academic thought and the processing technology of Zhuangxi Mongolian Medicine. Beijing University of Chinese Medicine; 2015.
4. Guo CP, Ma YL, Li HC, et al. Study on the occurrence state of calcium in mineral Medicine and its products of Mongolian Medicine. Jilin Traditional Chinese Medicine, 1995; 3: 43.
5. Wen YQ. Determination of calcium sulfate in Hanshui stone of Mongolian medicine by EDTA titration. Journal of Pharmaceutical Analysis. 1995; 1: 50.
6. Bao LD, Ao LQQ, Zhao YY. Determination of 15 elements in Zhuangxi Liuwei Powder of Mongolian Medicine by Inductive Combined Plasma Atomic Emission Spectrometry (ICP-AES). Chinese Journal of Inorganic Analytical Chemistry. 2016; 6(2): 58-60.
7. Zhang X, Xu LS, Xu XX, et al. Study on the effect of 80% ethanol extract of Cyanoyang on the prevention and treatment of osteoporosis in ovariectomized rats. Pharmacology and Clinic of Chinese Materia Medica. 2017; 33(3): 101-104.
8. Zhu G, Sun HB, Xu G. meat extract from the treatment of ovarian osteoporosis in rats and its mechanism. Journal of Jilin University (Medical Science Edition). 2018; 11(1): 68-70.
9. Wu HY, Zhang LL, Feng XM, et al. Effect of drug-containing serum of cyanoyang on proliferation, differentiation and mineralization of MC3T3-E1 osteoblasts. Chinese Medicine and Clinic. 2019; 10(1): 23-26.
10. The Obstetrics and Gynecology Expert Committee of the Osteoporosis Branch of the Chinese Geriatrics and Geriatrics Society and the Training Department for Perimenopausal Osteoporosis Prevention and Control. Consensus among Experts on the Prevention and Treatment of Osteoporosis in Perimenopausal and Postmenopausal Women. 2020; 48(8): 903-908. doi: 10.3969/j.issn.2095-8552.2020.08.009
11. Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporosis lnt. 2018; 29(5): 1049-1055.
12. Zhu SY, Deng Y, Wang YF, et al. Bone protection for early menopausal women in China: Standard or half-dose estrogen with progestin? A one-year prospective randomized trail. Gynecol Endocrinol. 2019; 35(2): 165-169.
13. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society* clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019; 104(5): 1595-1622.
14. Tubuxin T, Seesregdorj S. Clinical efficacy observation of Mongolian medicine Zhuangxi-4wei powder in the treatment of 60 cases of primary osteoporosis. Chinese Journal of Ethnic Medicine. 2019, 25(1): 2. doi: 10.3969/j.issn.1006-6810.2019.01.011
15. Wurihan. Clinical study of Mongolian medicine Zhuang Xi 4 Wei powder combined with calcium carbonate D3 tablets in the treatment of postmenopausal osteoporosis. Inner Mongolia National University; 2024.
16. Tang BB, Yuan YF, Liu K, et al. Study on the mechanism of Gushukang granule affecting the treatment of postmenopausal osteoporosis with exosomes derived from osteoclasts. Chinese Journal of Integrated Traditional Chinese and Western Medicine. 2024; 44(03): 339-347.
17. Zheng ZJ, Shu B, Zhao ST, et al. Effects of Gushukang granule on bone loss and osteoclast apoptosis in ovariectomized osteoporotic mice model. Journal of Traditional Chinese Medical Sciences. 2020; 35(7): 5.
18. Huang SW, Tian HJ, Guo ZY, et al. Clinical study of Gushukang granule combined with raloxifene in the treatment of postmenopausal osteoporosis. Modern Medicine & Clinic. 2023; 38(7): 1728-1732.
19. Ge J, Wang H, Zheng H, et al. Expert Consensus on the Prevention and Treatment of Primary Osteoporosis with Traditional Chinese Medicine. Chinese Journal of Osteoporosis, 2020, 26(12): 7-15. doi: 10.3969/j.issn.1006-7108.2020.12001
20. Liu Y, Pei YC, Wang XY, et al. Effect of Mongolian medicine blue thorn on estrogen receptor mRNA expression in bone tissue of ovariectomized rats. Journal of Inner Mongolia Medical University. 2017; 39(3): 249-253.
21. Xu P, Guo X, Zhang YG, et al. Effect and mechanism of retinoic acid induced osteoporosis in rats. Journal of Sichuan University (Medical Edition). 2005; 36(2): 229-232.
22. Hu B, Li QN, Li ZY, et al. Experimental study on changes of bone metabolism induced by retinoic acid in female rats. Chinese Journal of Osteoporosis. 1997; 3(1): 12.
23. Zhang MM. Regulation of bone metabolism by estrogen and estrogen receptor. Chinese Journal of Osteoporosis. 2019; 25(5): 704-708.
24. Li W, Zhang B, Zhang YW, et al. Research progress of estrogen regulation of bone metabolism. Chinese Journal of Osteoporosis. 2017; 23(2): 262-266.
25. Farzaneh S, Zarghi A. Estrogen receptor ligands: A review (2013–2015). Scientia Pharmaceutica. 2016; 84(3): 409-427.
26. Wu ZY, Liu JY, Li ZC. Guguishan Gushukang Granule for prevention and treatment of osteoporosis. Journal of Inner Mongolia University for Nationalities (Natural Science Edition). 2004; 19(2): 225-228.
27. Zheng ZJ, Shu B, Zhao ST, et al. Effect of Gushukang Granule on bone loss and osteoclast apoptosis in ovariectomized mouse model of osteoporosis. Chinese Journal of Traditional Chinese Medicine (formerly Chinese Medical Journal). 2020; 35(7): 3647.
28. Sun XQ. Molecular mechanism of estradiol regulation of mitochondrial autophagy in MC3T3-E1 cells through G protein-coupled estrogen receptor 30 (GPR30)/ERK1/2 signaling pathway (Chinese). Shenyang: China Medical University; 2018.
29. Müller ST, Keiler AM, Krǎker K, et al. Influence of estrogen on individual exercise motivation and bone protection in ovariectomized rats. Laboratory Animals. 2018; 52(5): 479-489.
30. Lin PI, Tai YT, Chan WP, et al. Estrogen/ERα signaling axis participates in osteoblast maturation via upregulating chromosomal and mitochondrial complex gene expressions. Oncotarget. 2017; 9(1): 1169-1186. doi: 10.18632/oncotarget.23453
31. Wu G, Xu R, Zhang P, et al. Estrogen regulates stemness and senescence of bone marrow stromal cells to prevent osteoporosis via ERβ‐SATB2 pathway. Journal of Cellular Physiology. 2017; 233(5): 4194-4204. doi: 10.1002/jcp.26233
Copyright (c) 2024 Tubuxin, Seesregdorj Suregjid, Dorjbat Sosorburam
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
